Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Significantly Refreshed Board Overseeing Successful Execution of Amarin's Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa's Slate in Every Critical Area

Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership

GREENWICH, Conn.--( BUSINESS WIRE )--Sarissa Capital Management LP (“Sarissa”) today issued the following letter to fellow shareholders of Amarin Corporation plc (NASDAQ: AMRN):

Sarissa Capital Urges Amarin Shareholders to Vote the Blue Card by February 22 to Fix Amarin for the Benefit of Shareholders

Urges Shareholders to Vote “AGAINST” Sarissa's Proposals on the WHITE Proxy Card

Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders

Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022 Marks 7th Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets Since 2022

Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved By Medsafe In New Zealand

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the SVB Securities Global Biopharma Conference.

Amarin to Present at SVB Securities Global Biopharma Conference

Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.

Amarin Corporation (AMRN) Down 13% in One Week: Here's Why

Amarin's tussle with its largest stakeholder doesn't appear to be sitting well with shareholders.

Why Amarin Stock Tumbled This Week

Arrival Group

Oatly

The changing of the calendar has brought a new sentiment to Wall Street. Many of 2022's biggest losers such as meme stocks, SPACs and penny stocks are suddenly enjoying strong rallies once again.

3 Penny Stocks to Sell in January Before They Peter Out

-- Board Refreshment Process Has Been Comprehensive, Independent and Transparent; Sarissa's Candidates Are Not Qualified Versus Recently Appointed Board Members -- -- Amarin Recognizes Shareholder Frustration with U.S. IP Loss And Has Taken Decisive Action with a New Strategy, New Team and New Board --

Amarin Responds to Inaccurate and Misleading Statement by Sarissa

GREENWICH, Conn.--( BUSINESS WIRE )--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN):

Sarissa Capital Calls Out Amarin's Sham Board Refreshment

Fintel reports that Sarissa Capital Management LP has filed a 13D/A form with the SEC disclosing ownership of 25,210,000 Amarin Corporation plc (ADR) (US:AMRN).

Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees

Amarin Corporation (AMRN) expects to generate total revenues in the range of $88-$90 million in fourth-quarter 2022. Share price rises following the announcement.

Amarin's (AMRN) Q4 Preliminary Revenues Top Expectations

Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management Highlights Significant Board Refreshment, Operational and Financial Improvements and Engagement with Sarissa Capital Management

Amarin Comments on Sarissa's Notice to Call a Special Meeting of Amarin Shareholders

Amarin Corporation plc (NASDAQ:AMRN ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 8:15 PM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer [Call Starts Abruptly] -- in Europe.

Amarin Corporation plc (AMRN) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)

Sarissa Capital Submits Notice to Call a Special Meeting of Amarin Shareholders to Add Directors and Remove Chairman Per Wold-Olsen

U.S.-listed shares of Amarin Corp. PLC AMRN, +16.22% rallied about 17% in trading on Tuesday afternoon after the company shared better-than-expected sales estimates for 2022. In a news release and during a presentation at the J.P.

Amarin's stock is up 17% on strong revenue estimates for 2022

-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 --

Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023

-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin's Board –-

Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP

Ardelyx

3 penny stocks to watch this week. The post Penny Stocks To Buy In 2023?

Penny Stocks To Buy In 2023? 3 To Watch In January

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin's president and chief executive officer, is scheduled to participate at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference

-- Amarin Continuing Process for Obtaining National Pricing and Reimbursement in Switzerland in the Course of 2023 -- -- Swissmedic Approval Underpins Company's Presence and Expansion in Switzerland as its Regional Commercial Hub for Europe --

Amarin Announces VAZKEPA® (icosapent ethyl) Receives Regulatory Approval in Switzerland

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Amarin (AMRN) Stock Might be a Great Pick

Amarin Corporation plc (NASDAQ:AMRN ) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 9:40 AM ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Michael Yee We'll get stared. Hey, it's Michael Yee here, Senior Biotechnology Analyst, at Jefferies.

Amarin Corporation plc (AMRN) Presents at 13th Annual Jefferies London Healthcare Conference 2022 (Transcript)

The product most readily identified with the company will soon hit pharmacy shelves in Australia.

Why Amarin Stock Was a Winner Today

-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 --

News for Amarin Corporation Plc Stock (AMRN)